Resultados de la búsqueda 221-230 of 9165 for Drug-resistant TB
... Resistant To Current Standard Of Care Treatments. Rochester, Minn. This phase 1b trial is an open-label study designed to assess the safety, tolerability ...
... resistant). Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an ...
... of diagnosis and effectiveness of cancer treatment. A Study to Analyze ... Treatment Resistant Depression Subcallosal Cingulate Network. Rochester, Minn ...
PARP inhibitors are a type of targeted therapy. Adding abemaciclib to olaparib may work better to treat recurrent platinum-resistant ovarian cancer. Testing ...
The overall goal of this research is to investigate potential differences in the regulation of skin blood flow in individuals with spinal cord injury. Analysis ...
The importance of prioritizing mental health for the LGBTQ+ community ... Mayo Clinic Q&A podcast: Combatting drug shortages July 26, 2022, 05:00 a.m. CDT.
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?